

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Withdrawn) An isolated polynucleotide comprising a sequence selected from the group consisting of:

- (a) sequences provided in SEQ ID NOs:442, 447, 450 and 467;
- (b) complements of the sequences provided in SEQ ID NOs:442, 447, 450 and 467;
- (c) sequences consisting of at least 10 contiguous residues of a sequence provided in SEQ ID NOs:442, 447, 450 and 467;
- (d) sequences that hybridize to a sequence provided in SEQ ID NOs:442, 447, 450 and 467, under highly stringent conditions;
- (e) sequences having at least 75% identity to a sequence of SEQ ID NOs:442, 447, 450 and 467;
- (f) sequences having at least 90% identity to a sequence of SEQ ID NOs:442, 447, 450 and 467; and
- (g) degenerate variants of a sequence provided in SEQ ID NOs:442, 447, 450 and 467.

2. (Canceled)

3. (Withdrawn) An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.

4. (Withdrawn) A host cell transformed or transfected with an expression vector according to claim 3.

5. (Withdrawn) An isolated antibody, or antigen-binding fragment thereof, that specifically binds to a polypeptide of claim 2.

6. (Withdrawn) A method for detecting the presence of a cancer in a patient, comprising the steps of:

- (a) obtaining a biological sample from the patient;
- (b) contacting the biological sample with a binding agent that binds to a polypeptide of claim 2;
- (c) detecting in the sample an amount of polypeptide that binds to the binding agent; and
- (d) comparing the amount of polypeptide to a predetermined cut-off value and therefrom determining the presence of a cancer in the patient.

7.-8. (Canceled)

9. (Withdrawn) An oligonucleotide that hybridizes to a sequence recited in SEQ ID NOs:442, 447, 450 and 467 under highly stringent conditions.

10. (Withdrawn) A method for stimulating and/or expanding T cells specific for a tumor protein, comprising contacting T cells with at least one component selected from the group consisting of:

- (a) polypeptides according to claim 2;
- (b) polynucleotides according to claim 1; and
- (c) antigen-presenting cells that express a polynucleotide according to claim 1,

under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells.

11. (Withdrawn) An isolated T cell population, comprising T cells prepared according to the method of claim 10.

12.-14. (Canceled)

15. (Withdrawn) A method for determining the presence of a cancer in a patient, comprising the steps of:

- (a) obtaining a biological sample from the patient;
- (b) contacting the biological sample with an oligonucleotide according to claim 9;
- (c) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; and
- (d) compare the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value, and therefrom determining the presence of the cancer in the patient.

16. (Withdrawn) A diagnostic kit comprising at least one oligonucleotide according to claim 9.

17. (Withdrawn) A diagnostic kit comprising at least one antibody according to claim 5 and a detection reagent, wherein the detection reagent comprises a reporter group.

18. (Withdrawn) A method for the treatment of lung cancer in a patient, comprising the steps of:

- (a) incubating CD4+ and/or CD8+ T cells isolated from a patient with at least one component selected from the group consisting of: (i) polypeptides according to claim 2; (ii) polynucleotides according to claim 1; and (iii) antigen presenting cells that express a polypeptide of claim 2, such that T cell proliferate;
- (b) administering to the patient an effective amount of the proliferated T cells,

and thereby inhibiting the development of a cancer in the patient.

19. (Withdrawn) An isolated antibody, or antigen-binding fragment thereof, that specifically binds to a lung tumor protein that comprises a polypeptide having an amino acid sequence provided in SEQ ID NO:441 or 443, or an amino acid sequence that is encoded by a polynucleotide having the sequence provided in SEQ ID NO:442 or a complement thereof.

20. (Currently Amended) An immunogenic composition comprising an adjuvant, wherein said adjuvant induces a predominantly Th1-type response, and a polypeptide selected from the group consisting of:

(i) a polypeptide comprising the amino acid sequence provided in SEQ ID NO:176, or a portion thereof;

(ii) a polypeptide comprising an amino acid sequence having at least 90% identity to the sequence provided in SEQ ID NO:176, or a portion thereof;

wherein said polypeptide contains an amino acid sequence that is capable of stimulating T cells that are specific for an amino acid sequence present in the polypeptide set forth in SEQ ID NO:176, and wherein said polypeptide is useful for the detection of lung cancer.

21. (Previously Presented) The immunogenic composition according to claim 20, wherein the adjuvant comprises an adjuvant selected from the group consisting of a monophosphoryl lipid A, an aluminum salt, QS21, Montanide ISA 720, SAF, ISCOMS, MF-59, SBAS-2, SBAS-4, Detox, RC-529, and an aminoalkyl glucosaminide 4-phosphate.

22. (Previously Presented) The immunogenic composition according to claim 20, wherein said polypeptide comprises amino acid positions 37-55 of the amino acid sequence provided in SEQ ID NO:176.

23. (Previously Presented) The immunogenic composition according to claim 20, wherein said polypeptide comprises amino acid positions 41-51 of the amino acid sequence provided in SEQ ID NO:176.